Changing face of health-care associated fungal infections.

Détails

ID Serval
serval:BIB_F26B68B9E05F
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Changing face of health-care associated fungal infections.
Périodique
Current Opinion in Infectious Diseases
Auteur(s)
Bille J., Marchetti O., Calandra T.
ISSN
0951-7375
Statut éditorial
Publié
Date de publication
08/2005
Peer-reviewed
Oui
Volume
18
Numéro
4
Pages
314-319
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review
Résumé
PURPOSE OF REVIEW: The purpose of this review was to evaluate recent publications on the epidemiology, diagnosis and management of invasive fungal infections. RECENT FINDINGS: Epidemiological surveys have highlighted significant differences between Europe and the United States regarding the incidence and etiology of Candida bloodstream infections. Today, invasive aspergillosis is occurring in a much broader patient population than the classical immunocompromised hosts and includes mechanically ventilated intensive care unit patients and patients receiving corticosteroids for treatment of chronic lung diseases. Diagnosis is often delayed in these patients and prognosis is dismal. Measurement of galactomannan, mannan and antimannan antibodies, and beta-(1-3)-D-glucan may help to speed up diagnosis. The epidemiology of invasive mold infections is changing. The frequency of non-fumigatus Aspergillus species is increasing, uncommon hyalo-or phaeo-hyphomycoses are emerging and breakthrough mold infections intrinsically resistant to azoles have been reported. Clinical trials have shown that new azoles and echinocandins are as efficacious as amphotericin B or fluconazole for the treatment of eosophageal or invasive candidiasis, for prophylaxis of invasive fungal infections in transplant patients, or for empirical antifungal therapy in patients with persistent fever and neutropenia. SUMMARY: Recent data suggest that the epidemiology of invasive fungal infections may be changing with the emergence of uncommon molds and the occurrence of invasive aspergillosis in 'nonclassical' immunocompromised hosts. New diagnostic tools and improved antifungal agents are available to facilitate early diagnosis and offer new treatment options.
Mots-clé
Antifungal Agents/therapeutic use, Communicable Diseases, Emerging/epidemiology, Cross Infection/epidemiology, Cross Infection/microbiology, Humans, Mycoses/drug therapy, Mycoses/epidemiology, World Health
Pubmed
Web of science
Création de la notice
25/01/2008 14:33
Dernière modification de la notice
03/03/2018 22:40
Données d'usage